Nothing currently in dispute alters the fact that the industry groups agreed to a shift in the use of legal these terms which delivers a dramatic and probably irreversible expansion in the government's power to extract price reductions from companies with PBS-listed medicines. …
Why would it take these powers if it did not intend to use them?
September 28, 2022 Latest NewsBioPharmaComment
Latest Video
Georgia Forrest
New Stories
-
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News -
BCEC partners with Life Sciences Queensland to launch bursary for next-gen bio innovation leaders
February 10, 2026 - - Australian Biotech -
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 - - Australian Biotech -
Algorae expands commercial footprint with new licensing deal
February 10, 2026 - - Australian Biotech -
Immutep reaches midpoint in global Phase 3 lung cancer trial
February 10, 2026 - - Australian Biotech -
Molecule2Market appoints inaugural CEO to lead next phase of growth
February 10, 2026 - - Australian Biotech -
Can we keep avoiding the simplest of all questions in a shifting medicines global order?
February 10, 2026 - - Latest News